Opendata, web and dolomites

EpiTarget

Epigenome-targeted therapy for cholangiocarcinoma.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EpiTarget project word cloud

Explore the words cloud of the EpiTarget project. It provides you a very rough idea of what is the project "EpiTarget" about.

molecular    translational    crispr    cholangiocarcinogenesis    surviving    architecture    phenotypic    rescue    expertise    plan    extensively    patient    curative    breaking    myself    accomplishment    virtually    first    patients    epi    treatment    neoplastic    prompting    genomics    jesper    dr    hepatobiliary    epimutation    mutations    andersen    editing    escalating    optimal    world    achilles    expansive    carry    enzymes    therapeutic    drug    palliative    chemotherapy    cca    unlike    supervised    researcher    broaden    prognosis    models    clarify    anti    data    lesions    deep    manipulation    expert    independent    sexes    sequencing    enzymatic    underpin    global    bio    transferable    benefit    cancer    epigenomic    acting    gt    compare    reversible    for    diagnosis    view    clinical       skills    comprise    epigenetic    scientific    screen    recurrent    epigenome    cellular    streamline    demographic    malignancy    deluge    clinic    point    greatest    epigenomics    therapy    cholangiocarcinoma    intrinsically    abysmal    epimutations    turning    vivo    devastating    70    draw    time    accordingly    rates    versus    mortality    bank    vitro    heel    intractable    unmet    exacerbating   

Project "EpiTarget" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://www.bric.ku.dk/Research/andersen-group/
 Total cost 200˙194 €
 EC max contribution 200˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2019-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 200˙194.00

Map

 Project objective

For > 70% of cholangiocarcinoma (CCA) patients, no curative treatment is available at time of diagnosis and they proceed directly to palliative chemotherapy with virtually 0% surviving at 5 years. Breaking overall cancer trends, CCA mortality rates are escalating among both sexes in the EU, exacerbating this clinical demographic of intractable patients. Recently, a deluge of deep sequencing studies have identified recurrent mutations in epigenetic enzymes in CCA, prompting a turning point in our view of the molecular architecture of this devastating malignancy. Unlike traditional mutations, epigenetic lesions or ‘epimutations’ are intrinsically reversible and, therefore, may comprise an optimal Achilles heel to target for therapeutic benefit. However, to streamline epigenome-driven therapy to the clinic, we first need to clarify molecular and cellular responses to epigenetic manipulation in different CCA models. Accordingly, I have 3 specific objectives of this proposal: i) I plan to carry out a comprehensive in vitro epi-drug screen to determine which enzymatic targets have the greatest anti-neoplastic activity; from this, ii) I will characterize the epigenomic changes that underpin such phenotypic rescue; finally, iii) I will compare the therapeutic effects of the top global-acting epi-drug versus target-specific epigenetic editing (Epi-CRISPR) of the most recurrent epimutation in vivo. Accomplishment of these objectives will improve our understanding of cholangiocarcinogenesis and also address the unmet clinical need for novel therapeutic targets in this cancer demographic with abysmal prognosis. The project will be supervised by Dr. Jesper Andersen, a world-leading expert in hepatobiliary cancer genomics, and will draw extensively on his expansive patient bio- and data-bank. Through this work, I aim to broaden my scientific expertise (including technical and transferable skills) and to establish myself as an independent researcher in translational epigenomics.

 Publications

year authors and title journal last update
List of publications.
2018 Chirag Nepal Colm J. O\'Rourke Douglas V.N.P. Oliveira Andrzej Taranta Steven Shema Prson Gautam Julien Calderaro Andrew Barbour Chiara Raggi Krister Wennerberg Xin W. Wang Anja Lautem Lewis R. Roberts Jesper B. Andersen
Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma
published pages: 949-963, ISSN: 1527-3350, DOI:
Hepatology 68(3) 2019-09-02
2018 Colm J.O\'Rourke, Patricia Munoz-Garrido, Esmeralda L.Aguayo, Jesper B.Andersen
Epigenome dysregulation in cholangiocarcinoma
published pages: 1423-1434, ISSN: 0925-4439, DOI:
Biochimica et biophysica acta - Molecular basis of disease Volume 1864, Issue 4, Part B 2019-09-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPITARGET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPITARGET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

DGLC (2019)

Domain-general language control: Evidence from the switching paradigm

Read More  

POLINFO (2020)

Information encoding to polymers

Read More  

THE CROSSMODAL BRAIN (2020)

Neural mechanisms of crossmodal activity in blind and sighted individuals

Read More